Biology Reference
In-Depth Information
26. Jackson PE, Hall CN, Badawi AF, O'Connor PJ, Cooper DP,
Povey AC. Frequency of Ki-ras mutations and DNA alkylation in
colorectal tissue from individuals living in Manchester.
Mol
Carcinog
1996;
46. Gerson SL, et al. Comparison of O6-alkylguanine-DNA alkyl-
transferase activity based on cellular DNA content in human, rat
and mouse tissues.
Carcinogenesis
1986;
9.
47. Schold Jr S, et al. O6-Alkylguanine-DNA alkyltransferase and
sensitivity to procarbazine in human braintumor xenografts.
J Neurosurg
1989;
7
:745
e
9.
27. Gerson SL. MGMT: its role in cancer aetiology and cancer ther-
apeutics.
Nat Rev Cancer
2004;
:12
16
e
7.
48. Dolan ME, Pegg AE.
O
6
-Benzylguanine and its role in chemo-
therapy.
Clin Cancer Res
1997;
:573
70
e
307.
28. Gerson SL, et al. Modulation of nitrosourea resistance in human
colon
:296
4
e
47.
49. Goodtzova K, Kanugula S, Edara S, Pauly GT, Moschel RC,
Pegg AE. Repair of O
6
-benzylguanine by the
Escherichia coli
Ada
and Ogt and the human O
6
-alkylguanine-DNA alkyltransferase.
J Biol Chem
1997;
:837
3
e
by O
6
-methylguanine.
cancer
Biochem Pharmacol
17.
29. Lee SM, Thatcher N, Dougal M, et al. Dosage and cycle effects of
dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA
alkyltransferase in human peripheral blood mononuclear cells.
Br
J Cancer
1993;
1992;
:1101
43
e
9.
50. Pegg AE, Kanugula S, Edara S, Pauly GT, Moschel RC,
Goodtzova K. Reaction of O
6
-benzylguanine-resistant mutants
of human O
6
-alkylguanine-DNA alkyltransferase with O
6
-benzyl-
guanine in oligodeoxyribonucleotides.
272
:8332
e
21.
30. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations
override alkyltransferase in conferring resistance to temozolo-
mide but not
:216
67
e
J Biol Chem
1998;
:
273
to 1,3-bis(2-chloroethyl)nitrosourea.
Cancer Res
7.
51. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-
alkylguanine-DNA alkyltransferase activity by O6-benzylgua-
nine provides a means to evaluate the role of this protein in
protection against carcinogenic and therapeutic alkylating agents.
PCNA
1990;
10863
e
9.
31. Gerson SL, Willson JK. O6-Alkylguanine-DNA alkyltransferase.
A target for the modulation of drug resistance.
Hematol Oncol Clin
NAm
1995;
1996;
:5375
56
e
50.
32. Pegg AE. Repair of O6-alkylguanine by alkyltransferases.
Mutat
Res
2000;
:431
9
e
72.
52. DolanME, Roy SK, FasanmadeA, Paras PR, Schilsky RL, RatainMJ.
O
6
-Benzylguanine in humans: metabolic, pharmacokinetic and
pharmacodynamic findings.
JClinOncol
1998;
:5368
87
e
100.
33. Daniels DS, Tainer JA. Conserved structural motifs governing the
stoichiometric repair of alkylated DNA by O
6
-alkylguanine-DNA
alkyltransferase.
Mutat Res
2000;
:83
462
e
10.
53. Watson AJ, Sabharwal A, Thorncroft M, et al. Tumor O(6)-
methylguanine-DNA methyltransferase inactivation by oral
lomeguatrib.
Clin Cancer Res
2010;
:1803
16
e
63.
34. Wibley JE, Pegg AE, Moody PC. Crystal structure of the human
O
6
-alkylguanine-DNA alkyltransferase.
Nucleic Acids Res
2000;
:151
460
e
9.
54. Phillips WP, Willson JKV, Markowitz SD, et al. O
6
-Methyl-
guanine-DNA methyltransferase (MGMT) transfectants of a 1,3-
bis(2-chloroethyl)-1 nitrosourea (BCNU)-sensitive colon cancer
cell line selectively repopulate heterogeneous
MGMT
รพ
/
MGMT
xenografts after BCNU and
O
6
-benzylguanine plus BCNU.
Cancer Res
1997;
16
:743
e
401.
35. Loktionova NA, Xu-Welliver M, Crone T, Kanugula S, Pegg AE.
Mutant forms of O
6
-alkylguanine-DNA alkyltransferase protect
CHO cells from killing by BCNU plus O
6
-benzylguanine or O
6
-8-
oxo-benzylguanine.
Biochem Pharmacol
1999;
28
:393
e
44.
36. Xu-Welliver M, Leitao J, Kanugula S, Pegg AE. Alteration of the
conserved residue tyrosine-158 to histidine renders human O6-
alkylguanine-DNA alkyltransferase insensitive to the inhibitor
O6-benzylguanine.
Cancer Res
59: 1514-19.
37. Pegg AE, Byers TL. Repair of DNA containing O
6
-alkylguanine.
FASEB J
1992;
:237
58
e
23.
55. Dolan ME, Larkin GL, English HF, et al. Depletion of O
6
-alkyl-
guanine-DNA alkyltransferase activity in mammalian tissues and
human tumor xenografts in nude mice by treatment with O
6
-
methylguanine.
Cancer Chemother Pharmacol
1989;
:4817
57
e
8.
56. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolo-
mide in the treatment of central nervous system tumor xeno-
grafts.
Cancer Res
1995;
25
:103
e
10.
38. Pegg AE, Dolan ME, Moschel RC. Structure, function and inhi-
bition of O
6
-alkylguanine-DNA alkyltransferase.
Prog Nucleic
Acid Res Mol Biol
1995;
:2302
6
e
7.
57. Spiro TP, Gerson SL, Liu L, et al. O
6
-benzylguanine: A clinical
trial establishing the biochemical modulatory dose in tumor
tissue for alkyltransferase-directed DNA repair.
Cancer Res
1999;
:2853
55
e
223.
39. Pegg AE. Repair of O6-alkylguanine by alkyltransferases.
Mutat
Res
2000;
:167
51
e
100.
40. Samson L, Han S, Marquis JC, Rasmussen LJ. Mammalian DNA
repair methyltransferases shield O
4
MeT from nucleotide excision
repair.
Carcinogenesis
1997;
462
:83
e
10.
58. Friedman HS. Can O
6
-alkylguanine-DNA alkyltransferase
depletion enhance alkylator activity in the clinic?
Clin Cancer Res
2000;
59
:2402
e
24.
41. Paalman SR, Sung C, Clarke ND. Specificity of DNA repair
methyltransferases determined by competitive inactivation with
oligonucleotide substrates: evidence that
Escherichia coli
Ada
repairs O
6
-methylguanine and O
4
-methylthymine with similar
efficiency.
Biochemistry
1997;
:919
18
e
8.
59. Spiro TP, Gerson SL, Liu L, et al. O6-benzylguanine: a clinical
trial establishing the biochemical modulatory dose in tumor
tissue for alkyltransferase-directed DNA repair.
Cancer Res
1999;
59
:2967
6
e
10.
60. Woolford LB, Southgate TD, Margison GP, Milsorn MD,
Fairbairn LJ. The P140K mutant of humanO(6)-methylguanine-
DNA-methyltransferase (MGMT) confers resistance in vitro and
in vivo to temozolomide in combination with the novel MGMT
inactivator O(6)-(4-bromothenyl)guanine.
:2402
e
24.
42. Gerson SL, Willson JK. O6-Alkylguanine-DNA alkyltransferase.
A target for the modulation of drug resistance.
Hematol Oncol Clin
North Am
1995;
36
:11118
e
50.
43. Lindahl T, Sedgewick B, Sekiguchi M, Nakabeppu Y. Regulation
and expression of the adaptive response to alkylatingagents.
Annu Rev Biochem
1988;
:431
9
e
J Gene Med
2006;
:
8
34.
61. Lindahl T. DNA repair enzymes.
Annu Rev Biochem
1982;
29
e
57.
44. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-
linking and monoadduct repair in nitrosoureatreated human
tumor cells.
Nature
1980;
:133
57
e
87.
62. Hardeland U, Bentele M, Lettieri T, et al. Thymine DNA glyco-
sylase.
Prog Nucleic Acid Res Mol Biol
2001;
:61
51
e
53.
63. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Phar-
macologic disruption of base excision repair sensitizes mismatch
repair deficient and proficient colon cancer cells to methylating
agents.
Clin Cancer Res
1999;
:235
68
e
9.
45. Hickman MJ, Samson LD. Apoptotic signaling in response to
a single type of DNA lesion, O(6)-methylguanine.
Mol Cell
2004;
:727
288
e
14
:105
e
16.
5
:2908
e
17.
